Țară: Canada
Limbă: engleză
Sursă: Health Canada
LEVONORGESTREL
ACTAVIS PHARMA COMPANY
G03AD01
LEVONORGESTREL
0.75MG
TABLET
LEVONORGESTREL 0.75MG
ORAL
2
OTC
CONTRACEPTIVES
Active ingredient group (AIG) number: 0125218002; AHFS:
CANCELLED POST MARKET
2018-03-05
_ _ _Next Choice™ - Product Monograph _ _Page 1 of 32 _ PRODUCT MONOGRAPH NEXT CHOICE™ Levonorgestrel Tablets 0.75 mg House Standard EMERGENCY CONTRACEPTION ACTAVIS PHARMA COMPANY 6733 Mississauga Road, Unit 400 Mississauga, ON, Canada, L5N 6J5 Date of Preparation: June 26, 2014 Submission Control No: 174352 _ _ _Next Choice™ - Product Monograph _ _Page 2 of 32 _ TABLE OF CONTENTS PART I: HEALTH CARE PROVIDER INFORMATION .......................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS ..................................................................................................11 DOSAGE AND ADMINISTRATION ..............................................................................13 OVERDOSAGE ................................................................................................................13 ACTION AND CLINICAL PHARMACOLOGY ............................................................14 STORAGE AND STABILITY ..........................................................................................16 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................16 PART II: SCIENTIFIC INFORMATION ................................................................................17 PHARMACEUTICAL INFORMATION ..........................................................................17 CLINICAL TRIALS ..........................................................................................................18 DETAIL Citiți documentul complet